Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells
J Jiang, P Yang, X Xu, H Yuan, H Zhu - Anti-Cancer Drugs, 2024 - journals.lww.com
Liver cancer is a prevalent malignant tumor globally. The newly approved first-line drug,
donafenib, is a novel oral small molecule multi-tyrosine kinase inhibitor that has significant …
donafenib, is a novel oral small molecule multi-tyrosine kinase inhibitor that has significant …